Meeting
2022 ASCO Genitourinary Cancers Symposium
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
Authors
Vadim S Koshkin
University of California San Francisco, San Francisco, CA
Vadim S Koshkin , Guru P. Sonpavde , Clara Hwang , Begona Mellado , Gareth Tomlinson , Masashi Shimura , Michael Jon Chisamore , Maciej Gil , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04601857
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 501)
DOI
10.1200/JCO.2022.40.6_suppl.501
Abstract #
501
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.
First Author: Jeeyun Lee
Poster
2023 ASCO Annual Meeting
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
First Author: Nan Chen
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Annual Meeting
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
First Author: Vivek Subbiah